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The Crohn’s & Colitis Foundation has facilitated transformational research in pediatric inflammatory bowel disease (IBD), through the RISK and 
PROTECT studies, that has laid the groundwork for a comprehensive understanding of molecular mechanisms of disease and predictors of thera-
peutic response in children. Despite these advances, children have lacked timely and informed access to the latest therapeutic advancements in IBD. 
The Crohn's & Colitis Foundation convened a Pediatric Resource Organization for Kids with Inflammatory Intestinal Diseases (PRO-KIIDS) Clinical 
Innovations Meeting at the inaugural Crohn's and Colitis Congress in January 2018 to devise how to advance the care of children with IBD. The work-
ing group selected 2 priorities: (1) accelerating therapies to children with IBD and (2) stimulating investigator-initiated research while fostering sustain-
able collaboration; and proposed 2 actions: (a) the convening of a task force to specifically address how to accelerate pharmacotherapies to children 
with IBD and (b) the funding of a multicenter clinical and translational research study that incorporates the building of critical research infrastructure.
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INTRODUCTION
Children and adolescents with inflammatory bowel 
disease (IBD) have unique needs due to the importance of 
supporting growth and development. With the highest peak 
incidence of new diagnosis of IBD occurring before 20 years of 
age and the expectation of lifelong therapy, the development of 
innovative therapies for children and adolescents is a top prior-
ity and a current gap in patient care.1 Children and adolescents 
furthermore provide unique insights into the pathophysiology 
and natural history of IBD due to the strong genetic associ-
ation and decreased impact of environmental factors such as 
smoking and medications.
The Crohn’s & Colitis Foundation has actively sup-
ported pediatric research, initially by funding pediatric inves-
tigator-initiated studies. In 2003, the Foundation sponsored a 
clinical trials meeting that led to the development of criteria 
for differentiating between Crohn’s disease (CD) and ulcerative 
colitis (UC)2 and to the development of a composite clinical 
scoring system for pediatric ulcerative colitis.3, 4 In 2005, the first 
Challenges in Pediatric IBD meeting was held, which identi-
fied a number of research priorities, including genetics, bone 
health, growth, behavioral health, and quality improvement.5 
Subsequent initiatives arising from this meeting included a 
funded initiative on pediatric skeletal health (led by Francisco 
Sylvester)6 and the development of the multicenter Pediatric 
RISK Stratification study (led by Subra Kugathasan and Lee 
Denson). Success from the Foundation-funded RISK study in 
turn led to an National Institutes of Health–funded study eval-
uating predictors of complicated pediatric UC (the PROTECT 
study, led by Jeffrey Hyams). As these large cohort studies near 
completion, the Foundation convened a Pediatric IBD Clinical 
Innovations Meeting at the inaugural Crohn’s and Colitis 
Congress in January 2018 to devise how to accelerate the deliv-
ery of new therapies to children and adolescents with IBD.
The Pediatric Resource Organization for Kids with 
Inflammatory Intestinal Diseases (PRO-KIIDS) Clinical 
Innovations meeting involved representation from a wide num-
ber of stakeholders, including academia, industry, government, 
the Foundation, and parents of children with IBD (see the 
“Acknowledgments” for a full list of participants). At the con-
clusion of this meeting, 2 primary priorities were finalized: (1) 
expediting delivery of new therapies to children with IBD and 
(2) developing another large multicenter clinical and transla-
tional study for the PRO-KIIDS network.
STATEMENT OF PROBLEM
Children and adolescents with IBD lack data-driven and 
timely access to the newest pharmacotherapies available to 
adult patients. Research advances, including large-scale pediat-
ric trials necessary to bring new therapies to pediatric patients, 
require investment of significant resources to stimulate and sus-
tain collaboration across various stakeholders.
CURRENT PROGRESS
Collaborative research from the Foundation’s PRO-
KIIDS network has transformed our understanding of the 
multifactorial etiology of IBD, including genetics, the intestinal 
microbiome, environmental exposures, and immunological fac-
tors.7 The RISK study, which enrolled 1096 children with newly 
diagnosed CD with follow-up over approximately 3 years, char-
acterized the natural history of pediatric CD and demonstrated 
that early anti–tumor necrosis factor–alpha therapy was associ-
ated with a reduction in penetrating complications (abscess and 
internal fistulae), though not a reduction in fibrostenosing dis-
ease.8 A predictive model furthermore identified specific demo-
graphic, serologic, and transcriptomic elements associated with 
disease complications.9 The PROTECT study, a prospective 
cohort of 428 children with newly diagnosed UC, evaluated 
standardized therapy for UC in children and identified key pre-
dictors of treatment response.10 Both RISK and PROTECT are 
landmark PRO-KIIDS network studies that have accelerated 
the understanding of critically important aspects of CD and 
UC. They have fostered the development of risk stratification 
to individualize treatment strategies aimed to optimize long-
term health, beginning with childhood IBD diagnosis.
BUILDING ON SUCCESS
Although the RISK and PROTECT multicenter studies 
laid foundations for the development of therapeutic strategies 
for pediatric IBD, therapeutic options for children with IBD 
remain limited. The most transformative therapy for IBD, 
infliximab, did not achieve a Food and Drug Administration 
(FDA) label for pediatric patients until 8 years after the label 
was approved for adults with IBD. During this period, inflix-
imab was utilized off-label for children with CD and UC refrac-
tory to thiopurines; corticosteroids, with their extensive adverse 
effects, were employed broadly. The challenges of off-label use 
of medications for pediatric IBD and other pediatric diseases 
persist. Approximately 50% of pediatric medications in chroni-
cally ill children are used off-label to benefit individual patients. 
According to the American Academy of Pediatrics position 
statement on off-label use, “Off label use remains a persistent 
public health issue, especially, for infants, young children, 
and children with rare illnesses…. Much work remains to be 
done to ensure the best possible practice for therapeutic deci-
sion-making in pediatrics.”11 Currently, adalimumab in UC, 
certolizumab in CD, ustekinumab in CD, and vedolizumab in 
CD and UC all have adult but not pediatric indications.
At present, off-label use of medications for pediatric IBD 
is widespread despite the absence of rigorous pediatric phar-
macokinetic (pK) and pharmacodynamic (pD) data. This has 
resulted in the extrapolation of adult pK/pD data to children 
despite known differences in metabolic profile and physiology.12 
Though many new medications are available to adults, the lack 
of pediatric studies incorporated into drug development has 
severely limited the informed use of potentially disease course–
altering therapies in children. Numerous obstacles have made 
the execution of pediatric trials difficult, including a lack of 
uniform assessments of disease activity and clinical trial end 
points, suboptimal partnership with industry during drug 
development, lack of pediatric-specific multicenter research 
infrastructure, lesser financial incentive when compared with 
drug development for adult patients, and heightened logistical 
barriers and ethical issues in pediatric clinical trials.
In light of these issues specific to pediatric research, we 
propose (1) the development of a task force to specifically 
address the need to accelerate the delivery of new therapeutics 
to children with IBD and (2) the continued growth of rigorous, 
well-coordinated research in the pediatric population through 
the ongoing investment in novel investigator-initiated research 
studies, and with an explicit focus on creating sustainable infra-
structure to support future pediatric trials.
ACCELERATE THERAPIES TO CHILDREN 
WITH IBD
Pediatric gastroenterologists act as strong advocates for 
their patients, prescribing potentially life-altering medications in 
the absence of pK/pD and safety data, and often encounter third-
party payer hurdles. The Pediatric Research Equity Act, enacted in 
the United States in 2003,13 gives the FDA authority to mandate 
pharmaceutical companies to provide safety and effectiveness data 
for pediatric patients. However, the time frame is open, and market 
incentives to expedite the process are lacking. The 21st Century 
Cures Act, enacted in 2016,14 may accelerate drug approvals in 
general, but the implications for children remain unclear. Pediatric 
gastroenterologists need adequate dosing and safety data to effec-
tively prescribe medications to children; a system that fosters the 
availability of safer and more effective therapies to adults without 
inclusion of children further disadvantages this “vulnerable” pop-
ulation. Reform is necessary and can be achieved, through both 
mandates and incentives, and by partnering with regulatory bodies 
and pharmaceutical companies, to ensure this critical information 
is available at the time of initial FDA approval.
Several strategies may provide the requisite data to 
appropriately guide the dosing of new medications in pediatric 
patients and could concomitantly lead to pediatric indication in 
a timely manner—inclusion of adolescent (12–17 years) subjects 
in adult trials, extrapolation of adult pK/pD data, and creating 
a system to gather pK/pD phase II pediatric studies during late 
phase II/phase III clinical trials in adults. Adolescent inclusion 
could lead to approved indication for 70% of the pediatric IBD 
population, but study of drugs in a population of research sub-
jects with less experience with placebo-controlled trials may dis-
incentivize pharmaceutical companies to pursue this approach. 
Extrapolation may be more feasible and, if  paired with early 
pediatric pK/pD data, could sufficiently inform pediatric dosing.
Most IBD is treated with immune-suppressing agents, 
which run rare but serious risks of opportunistic infections and 
lymphoma. Such complications are particularly concerning to 
parents of children, who desire accurate data regarding the long-
term risks of medication. Obtaining accurate safety data on 
immune-modifying therapies in IBD necessitates robust, multi-
center, longitudinal, and coordinated safety monitoring. Industry-
sponsored registries, such as DEVELOP and CAPE, provide 
crucial data but are proprietary. A unified public drug safety reg-
istry, such as the CARRAnet registry developed by the pediatric 
rheumatology community, would provide more valuable informa-
tion about the natural history of pediatric IBD than individual 
company registries that only assess the safety of a single drug.
In addition to dosing and safety, global harmonization of 
clinical end points in pediatric IBD is essential. Currently, there 
is a lack of uniform data types and standard measures. The 
Clinical Data Interchange Standards Consortium (CDISC) 
facilitates the harmonization of terminology to be used across 
parties invested in clinical research, including the pharma-
ceutical industry, government agencies, academia, health care 
providers, subjects, patients, and technology providers, among 
others.15 CDISC standards have been applied to specific disease 
states, resulting in unified data elements pertinent to the disease, 
known as therapeutic area user guides (TAUGs). TAUGs have 
accelerated the discovery of biomarkers in polycystic kidney 
disease and malaria. The development of a TAUG for pediatric 
IBD, or IBD generally, would advance global harmonization of 
data and may accelerate drug development through reduction 
of inefficiency and fostering of collaboration.
A recent major change in the design of pediatric and adult 
IBD clinical trials has been the desire of regulatory bodies to 
de-emphasize composite end points of disease activity (eg, the 
Pediatric Crohn Disease Activity Index [PCDAI] and the Pediatric 
Ulcerative Colitis Activity Index [PUCAI]). Instead, the FDA and 
European Medicines Agency (EMA) have supported the devel-
opment of patient-reported outcomes (PROs) and the need for 
validated indices of endoscopic disease activity.16, 17 To address the 
need for reliable and valid PROs, 2 separate projects are underway 
to develop and validate PROs for Crohn’s disease (TUMMY-CD) 
and ulcerative colitis (TUMMY-UC) in pediatrics. These mea-
sures are being developed with the guidance of the FDA and 
EMA to ensure that they comply with regulatory standards that 
will apply to future drug development. Open and responsive 
dialogue between the FDA, EMA, and investigators is crucial 
to the timely development and validation of TUMMY-CD and 
TUMMY-UC. A coordinated effort to implement these measures 
in clinical trial design through partnership with industry should 
follow. Additional work needs to be done to further validate mea-
surements of endoscopic healing, such as the Simple Endoscopic 
Score for Crohn’s disease (SES-CD), and determine the need for 
central reading, interobserver variability, and reference timelines 
for expected endoscopic healing. The correlation between endo-
scopic disease activity and less invasive assessments (including 
disease activity measures, PROs, noninvasive biomarkers, and 
diagnostic imaging) should also be a focus of future research.
The pediatric population provides a unique opportunity 
to elucidate molecular mechanisms of disease and determine tar-
geted therapeutic approaches that incorporate biomarker guidance. 
Translational studies of the RISK and PROTECT cohorts hold the 
potential to provide a paradigm shift in delivering on the promise 
of applying the right therapy to the right patient at the right time. 
Incorporation of prospective multi-omic data into clinical trials is 
crucial, and academic–industry partnerships hold promise.
PROPOSED ACTION 1: CONVENE AND CHARGE 
TASK FORCE
We propose the convening of a task force with the charge 
to develop a strategic plan that spans academia, clinicians, 
industry, regulatory agencies, and patients/families to acceler-
ate new therapies to children with IBD. This task force should 
be composed of a pediatric gastroenterologist, IBD clinical 
trial researcher, drug development expert from industry, patient 
and caregiver, clinical research coordinator, biostatistician/
bioinformaticist, regulatory agency representative, formulary 
expert from a third-party payer, and a pediatric rheumatologist 
or oncologist with experience in well-developed research infra-
structure (Table 1).
The task force would determine the optimal strategy to 
ensure that dosing for pediatric IBD is available for newly devel-
oped therapies at the time of FDA approval (Fig. 1). This may 
include clinician/industry partnership during drug develop-
ment and advocacy for federal legislation. The task force would 
outline the optimal design of a patient safety registry in pediat-
ric IBD. This may align with current efforts underway. The task 
force would determine the optimal method to federate clinical 
trial data for pediatric IBD. This may include the creation of a 
TAUG with CDISC standards, a uniform structure of pediat-
ric study plans submitted to the FDA by industry, the use of 
“basket trial” methodology, and an overarching infrastructure 
for clinical trials, such as a master protocol or a shared control 
group. The task force may also clarify the role of biomarker 
development and investigation during drug development.
PROPOSED ACTION 2: COPRODUCTION 
OF NEW RESEARCH INITIATIVES WITH 
INFRASTRUCTURE
To build upon the collaborative research framework from 
RISK and PROTECT, we propose that future studies within 
the PRO-KIIDS network foster innovative investigator-initi-





















FIGURE 1. Opportunities to advance pharmacotherapies in pediatric IBD. Standardized measures include acvity indices, patient-reported outcomes, 
endoscopic score. Abbreviations: pD, pharmacodynamic; PhII, phase 2; PhIII, phase 3; pK, pharmacokine c.
TABLE 1. Proposed Task Force Membership
Clinical Pediatric gastroenterologist
Patient and caregiver
Pediatric rheumatologist or oncologist
Research IBD clinical trial researcher
Biostatistician and bioinformaticist
Clinical research coordinator
Industry Specialist on drug development
Regulatory Agency representative
Payer Formulary expert from third-party payer
future trials. Support for pilot studies will help facilitate the devel-
opment of young investigators and also help fund the study of 
high-risk, high-reward hypotheses with the potential to advance 
pediatric IBD research. Executing the completion of these proj-
ects in tandem with infrastructure building will allow continuity 
of research questions and expedite novel questions from hypoth-
esis-generating to validation and clinical application.
The infrastructure to help PRO-KIIDS sites be “tri-
al-ready” may include creation of database resources geared 
toward supporting clinical trials, developing centralized resources 
for sample collection and reading, and providing resources for 
research coordinator support and training (Fig. 2). Building of 
infrastructure that is transferrable among projects will benefit 
future investigators, eliminate waste, and expedite study design 
and implementation. Infrastructure development should incor-
porate nonexclusive resources that will facilitate interested sites 
to join any given PRO-KIIDS research consortium study.
Innovative pediatric studies on the role of genetics and 
environmental triggers may provide unique insight into under-
standing IBD pathogenesis. This knowledge may facilitate the 
development of novel technologies and therapeutic approaches 
that impact both children and adults. Projects assessing the 
validity of adult measures (ie, Short Endoscopic Index of CD 
Severity [SES-CD]) or endoscopic Mayo score in children may 
help facilitate the incorporation of children into adult trials, 
and similar projects to define end points in pediatric trials will 
also accelerate the delivery of therapies to children.
CONCLUSION
The future of IBD holds great promise for children. The 
Crohn’s & Colitis Foundation has facilitated transformational 
research in RISK and PROTECT that has laid the groundwork 
for a comprehensive understanding of molecular mechanisms of 
disease and predictors of therapeutic response in children. Despite 
these advances, children have lacked timely and informed access to 
the latest therapeutic advancements in IBD. The working group 
of the Pediatric IBD Clinical Innovations meeting at the inaugu-
ral Crohn’s & Colitis Foundation Congress selected 2 priorities to 
advance the care of children with IBD: (1) accelerating therapies 
to children with IBD and (2) stimulating investigator-initiated 
research while fostering sustainable collaboration. We recommend 
the convening of a task force to specifically address how to accel-
erate pharmacotherapies to children with IBD and the funding of 
a multicenter clinical and translational research study that incor-
porates the building of critical research infrastructure. The PRO-
KIIDS network has helped establish a foundation for pediatric 
IBD research, and notable opportunities exist for further break-
throughs utilizing a strong collaborative approach.
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